Robert Ainscow, Interim CEO and COO of ASP Isotopes Inc (NASDAQ:ASPI), sold 25,000 shares of common stock on November 25, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $5.769, for a total value of $144,225. ASPI shares currently trade at $6.22, up from the sale price and showing a 37.31% year-to-date return despite recent volatility.

The prices for the shares sold ranged from $5.54 to $6.015. This sale was executed under a Rule 10b5-1 trading plan adopted on December 13, 2024. Following the transaction, Ainscow directly owns 1,554,693 shares of ASP Isotopes Inc, representing a stake in the company's $690.42 million market cap. According to InvestingPro analysis, ASPI appears overvalued at current levels, with the company scheduled to report earnings on December 3. InvestingPro offers additional insights through its comprehensive Pro Research Report, available for over 1,400 US stocks.

In other recent news, ASP Isotopes Inc. reported its third-quarter 2025 earnings, highlighting a 24% year-to-date revenue increase in its radiopharmaceutical segment. Despite this growth, the company experienced a net loss from operations totaling $34.9 million. The company continues to focus on product development and facility expansion. Additionally, ASP Isotopes announced an extension of the deadline for completing its proposed acquisition of Renergen Limited. The new deadline is set for January 30, 2026, allowing more time to secure regulatory approval and third-party consents. This marks a further extension from the previously adjusted date of November 28, 2025. These recent developments indicate ongoing efforts in strategic growth and expansion for ASP Isotopes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.